OBJECTIVES: Dysregulation of miRNAs and their target genes contributes to the pathophysiology of autoimmune diseases. Circulating miRNAs may serve as diagnostic/prognostic biomarkers. We aimed to investigate the association between circulating miRNAs, disease activity and spinal involvement in patients with axial spondyloarthritis (AxSpA). METHODS: Total RNA was isolated from the plasma of patients with non-radiographic (nr)AxSpA, patients with ankylosing spondylitis (AS) and healthy controls (HC) via phenol-chloroform extraction. A total of 760 miRNAs were analysed with TaqMan® Low Density Arrays, and the expression of 21 miRNAs was assessed using single assays. RESULTS: Comprehensive analysis demonstrated the differential expression of miRNAs among patients with progressive spinal disease. Of the 21 miRNAs selected according to their expression patterns, the levels of miR-625-3p were significantly different between nr-AxSpA patients and HCs. We found no correlation between miRNA levels and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in nr-AxSpA patients. Selected miRNAs, such as miR-29a-3p, miR-146a-5p or miR-222-3p with an established role in extracellular matrix formation and inflammation were associated with spinal changes and/or disease activity assessed by BASDAI in AS patients, including miR-625-3p reflecting disease activity in AS with spinal involvement. CONCLUSIONS: Our data indicate that circulating miRNAs play a role in the pathogenesis of AxSpA and are also suggestive of their potential as biomarkers of disease progression. We hypothesize that differential systemic levels of miRNA expression reflect miRNA dysregulation at sites of spinal inflammation or bone formation where these molecules contribute to the development of pathophysiological features typical of AxSpA.

Center of Experimental Rheumatology University Hospital Zurich Zurich Switzerland

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the rheumatic diseases. 2011;70(6):896–904. doi: 10.1136/ard.2011.151027 PubMed DOI PMC

Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–37. doi: 10.1016/S0140-6736(11)60071-8 . PubMed DOI

Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis and rheumatism. 2008;58(3):649–56. doi: 10.1002/art.23260 . PubMed DOI

Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis research & therapy. 2009;11(2):221 doi: 10.1186/ar2642 PubMed DOI PMC

Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the rheumatic diseases. 2009;68(6):770–6. doi: 10.1136/ard.2009.108217 . PubMed DOI

Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Annals of the rheumatic diseases. 2013;72(6):815–22. doi: 10.1136/annrheumdis-2012-201766 PubMed DOI PMC

Prajzlerova K, Grobelna K, Pavelka K, Senolt L, Filkova M. An update on biomarkers in axial spondyloarthritis. Autoimmunity reviews. 2016;15(6):501–9. doi: 10.1016/j.autrev.2016.02.002 . PubMed DOI

Filkova M, Jungel A, Gay RE, Gay S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2012;26(3):131–41. doi: 10.2165/11631480-000000000-00000 . PubMed DOI

Filkova M, Aradi B, Senolt L, Ospelt C, Vettori S, Mann H, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Annals of the rheumatic diseases. 2014;73(10):1898–904. Epub 2013/07/31. doi: 10.1136/annrheumdis-2012-202815 PubMed DOI PMC

Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Annals of the rheumatic diseases. 2002;61 Suppl 3:iii9–23. Epub 2002/10/17. doi: 10.1136/ard.61.suppl_3.iii19 PubMed DOI PMC

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the rheumatic diseases. 2011;70(1):25–31. doi: 10.1136/ard.2010.133645 . PubMed DOI

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of rheumatology. 1994;21(12):2286–91. . PubMed

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8. doi: 10.1073/pnas.0804549105 PubMed DOI PMC

Carlsen AL, Schetter AJ, Nielsen CT, Lood C, Knudsen S, Voss A, et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis and rheumatism. 2013;65(5):1324–34. Epub 2013/02/13. doi: 10.1002/art.37890 . PubMed DOI PMC

Landskroner-Eiger S, Qiu C, Perrotta P, Siragusa M, Lee MY, Ulrich V, et al. Endothelial miR-17 approximately 92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(41):12812–7. doi: 10.1073/pnas.1507094112 PubMed DOI PMC

Zhao W, Wu C, Dong Y, Ma Y, Jin Y, Ji Y. MicroRNA-24 Regulates Osteogenic Differentiation via Targeting T-Cell Factor-1. International journal of molecular sciences. 2015;16(5):11699–712. doi: 10.3390/ijms160511699 PubMed DOI PMC

Hassan MQ, Gordon JA, Beloti MM, Croce CM, van Wijnen AJ, Stein JL, et al. A network connecting Runx2, SATB2, and the miR-23a~27a~24–2 cluster regulates the osteoblast differentiation program. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(46):19879–84. doi: 10.1073/pnas.1007698107 PubMed DOI PMC

Wang T, Xu Z. miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochemical and biophysical research communications. 2010;402(2):186–9. doi: 10.1016/j.bbrc.2010.08.031 . PubMed DOI

Li H, Li T, Wang S, Wei J, Fan J, Li J, et al. miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Stem cell research. 2013;10(3):313–24. Epub 2013/02/13. doi: 10.1016/j.scr.2012.11.007 . PubMed DOI

Hong Z, Hong H, Liu J, Zheng X, Huang M, Li C, et al. miR-106a Is Downregulated in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B and Associated with Enhanced Levels of Interleukin-8. Mediators of inflammation. 2015;2015:629862 doi: 10.1155/2015/629862 PubMed DOI PMC

Azevedo VF, Faria-Neto JR, Stinghen A, Lorencetti PG, Miller WP, Goncalves BP, et al. IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatology international. 2013;33(7):1779–83. Epub 2013/01/09. doi: 10.1007/s00296-012-2631-x . PubMed DOI

Xie Y, Zhang L, Gao Y, Ge W, Tang P. The Multiple Roles of Microrna-223 in Regulating Bone Metabolism. Molecules. 2015;20(10):19433–48. doi: 10.3390/molecules201019433 . PubMed DOI PMC

M'Baya-Moutoula E, Louvet L, Metzinger-Le Meuth V, Massy ZA, Metzinger L. High inorganic phosphate concentration inhibits osteoclastogenesis by modulating miR-223. Biochimica et biophysica acta. 2015;1852(10 Pt A):2202–12. doi: 10.1016/j.bbadis.2015.08.003 . PubMed DOI

Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis research & therapy. 2015;17:49 Epub 2015/04/11. doi: 10.1186/s13075-015-0555-z PubMed DOI PMC

Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. The Journal of clinical investigation. 2013;123(2):566–79. Epub 2013/01/17. doi: 10.1172/JCI65871 PubMed DOI PMC

Miyaki S, Nakasa T, Otsuki S, Grogan SP, Higashiyama R, Inoue A, et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis and rheumatism. 2009;60(9):2723–30. Epub 2009/08/29. doi: 10.1002/art.24745 PubMed DOI PMC

Peng JS, Chen SY, Wu CL, Chong HE, Ding YC, Shiau AL, et al. Amelioration of Experimental Autoimmune Arthritis Through Targeting of Synovial Fibroblasts by Intraarticular Delivery of MicroRNAs 140-3p and 140-5p. Arthritis & rheumatology. 2016;68(2):370–81. doi: 10.1002/art.39446 . PubMed DOI

Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis and rheumatism. 2011;63(6):1582–90. Epub 2011/03/23. doi: 10.1002/art.30321 . PubMed DOI

Xu HY, Wang ZY, Chen JF, Wang TY, Wang LL, Tang LL, et al. Association between ankylosing spondylitis and the miR-146a and miR-499 polymorphisms. PloS one. 2015;10(4):e0122055 Epub 2015/04/04. doi: 10.1371/journal.pone.0122055 PubMed DOI PMC

de la Rica L, Garcia-Gomez A, Comet NR, Rodriguez-Ubreva J, Ciudad L, Vento-Tormo R, et al. NF-kappaB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation. Genome biology. 2015;16:2 doi: 10.1186/s13059-014-0561-5 PubMed DOI PMC

Fukuda T, Ochi H, Sunamura S, Haiden A, Bando W, Inose H, et al. MicroRNA-145 regulates osteoblastic differentiation by targeting the transcription factor Cbfb. FEBS letters. 2015;589(21):3302–8. doi: 10.1016/j.febslet.2015.09.024 . PubMed DOI

Lv Q, Li Q, Zhang P, Jiang Y, Wang X, Wei Q, et al. Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets. BioMed research international. 2015;2015:504208 doi: 10.1155/2015/504208 PubMed DOI PMC

Huang J, Song G, Yin Z, Luo X, Ye Z. Elevated miR-29a expression is not correlated with disease activity index in PBMCs of patients with ankylosing spondylitis. Modern rheumatology / the Japan Rheumatism Association. 2014;24(2):331–4. doi: 10.3109/14397595.2013.854077 . PubMed DOI

Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology. 1989;124(6):2991–4. doi: 10.1210/endo-124-6-2991 . PubMed DOI

Le LT, Swingler TE, Crowe N, Vincent TL, Barter MJ, Donell ST, et al. The microRNA-29 family in cartilage homeostasis and osteoarthritis. Journal of molecular medicine. 2015. doi: 10.1007/s00109-015-1374-z . PubMed DOI PMC

Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis and rheumatism. 2010;62(6):1733–43. doi: 10.1002/art.27443 . PubMed DOI

Yu F, Cui Y, Zhou X, Zhang X, Han J. Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. Bioscience trends. 2011;5(2):46–51. Epub 2011/05/17. . PubMed

Song J, Jin EH, Kim D, Kim KY, Chun CH, Jin EJ. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA clinical. 2015;3:79–89. doi: 10.1016/j.bbacli.2014.11.009 . PubMed DOI PMC

Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokines

Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases?

Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis

S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity